Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan 20:8:23-33.
doi: 10.2147/PGPM.S39085. eCollection 2015.

Targeted treatments for multiple myeloma: specific role of carfilzomib

Dhivya Sugumar  1 , Jesse Keller  2 , Ravi Vij  2
Affiliations
Review

Targeted treatments for multiple myeloma: specific role of carfilzomib

Dhivya Sugumar et al. Pharmgenomics Pers Med. .

Abstract

Carfilzomib is a selective, irreversible proteasome inhibitor, initially approved in the US in 2012 as single-agent therapy for relapsed and refractory multiple myeloma. Numerous Phase II studies have evaluated carfilzomib in the relapsed and refractory as well as the newly diagnosed setting, and Phase III studies are entering their final analysis. Data continue to grow to support its use as both single-agent therapy and in combination with immunomodulatory and other novel agents. This review discusses the role of carfilzomib in the treatment of multiple myeloma. Its mechanism of action, pharmacokinetics, and role in clinical management will be reviewed.

Keywords: novel agents; proteasome inhibitor; relapsed and refractory; targeted therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. American Cancer Society Multiple Myeloma. Aug 10, 2014. Available from: http://www.cancer.org/cancer/multiplemyeloma/
    1. National Comprehensive Cancer Network Multiple Myeloma (Version 1.2015) Aug 10, 2014. Available from: http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. - PubMed
    1. van de Donk NW, et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev. 2011;37(4):266–283. - PubMed
    1. Orlowski M, Wilk S. Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex. Arch Biochem Biophys. 2000;383(1):1–16. - PubMed
    1. Rock KL, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994;78(5):761–771. - PubMed